This feature articles commemorates the 10-year anniversary of the FDA's first approval of an SGLT2 inhibitor on March 29, 2013 and provides a snapshot at the class's ascent into the treatment algorithms and guidelines for type 2 diabetes, heart failure, and chronic kidney disease.
There is a June 22 PDUFA date for obeticholic acid, which if approved would become the first FDA-approved treatment for NASH.
This research letter highlighted the results of an allergy work-up and of vaccinations for COVID-19 in patients with a suspicion of mRNA vaccine hypersensitivity.
The approval, which is for 4 mg naloxone hydrochloride nasal spray, marks the first OTC, nonprescription approval for a naloxone nasal spray and allows the product to be sold directly to consumers in a variety of retail locations well as online.
In this episode, hosts celebrate the 10-year anniversary of the approval of the first SGLT2 inhibitor, discuss announcements related to insulin pricing, and take a deep dive into 24-week data from the MOMENTUM trial.
A recent analysis showed that a combination treatment made of phosphate, adapalene, and benzoyl peroxide known as IDP-126 was well-tolerated and effective in pediatric participants with acne.
The comparative safety and effectiveness of analgesic medications for acute non-specific low back pain are unclear, highlighting the need for higher quality randomized controlled trials comparing different medications.
Smokers with TED showed less improvement in diplopia, proptosis, and overall clinical activity score compared to non-smokers.
A new cohort study suggested the number of days per week taking 8000 steps or more was associated with a decreased risk of all-cause and cardiovascular mortality.
Future research could explore the factors contributing to this disparity and identify effective interventions to reduce tobacco use in this population.
A silent disease characterized as a chronic cutaneous neuropathy, notalgia paresthetica has an unmet need yet to be fully understood and, dermatologists argue, an FDA-approved treatment could help improve understanding of the etiology and prevalence of this disease.
New data on peanut allergy and Pediatric Quality of Life Inventory scores sheds light on the burden of allergy on adolescents.
The results show 83% of patients in the combination group achieved clinical response at week 12, compared to 61% of the golimumab monotherapy group and 75% of the guselkumab group.
An analysis of more than 9000 adults aged 40 and older without known cardiovascular disease is shedding new light on the risk of myocardial infarction and mortality associated with subclinical coronary atherosclerosis.
In his recent interview, Lal described the condition of dystrophic epidermolysis bullosa in detail, going into the different forms it can take as well as his experiences treating the condition.
Patients in the top half of the cohort for both clinical severity and instability were at an increased risk of hospitalization than those at the bottom half of both dimensions
A systematic review and meta-analysis of more than 120 randomized trials offers new insight into the effects of weight regain on cardiometabolic risk up to 5 years after the cessation of a behavioral management program.
Investigators developed and validated a tool for daily assessment of asthma control that can be utilized in clinical trials as an endpoint.
Patients with rheumatoid arthritis have a greater risk of dementia, but do you know what influence different treatments for rheumatoid arthritis have on this risk? Test your knowledge with this quiz.
The expert consensus statement provides updated recommendations on evidence-based best practices for transcatheter LAAC, with a focus on endovascular devices.
As the US tries to move on from the pandemic, patients with long COVID-19 are fighting to regain normalcy while clinicians improve care plans and researchers search for answers.
The ANTICOVID clinical trial finds high-dose prophylactic anticoagulation reduces risk of de novo thrombosis in COVID-19 pneumonia.
The treatment is a first-in-class peptide derived from mTB Chaperonin 60.1 that is often involved in resetting the immune system. The treatment is being evaluated in patients with eosinophilic esophagitis and allergen sensitivity.
A cost-effectiveness analysis of the EAST – AFNET 4 trial indicated the health benefits of early rhythm control come at reasonable additional costs compared to usual care.
Our latest endocrine case report from Brady Pregerson, MD, features a patient in their mid-70s with a history of diabetes mellitus and end-stage kidney disease presenting with 6 days of gradually worsening right ear pain. Can you determine the correct diagnosis?
While nipocalimab is under consideration as the first marketed drug for HDFN, clinicians consider the importance of awareness and dedicated research into the rare disease.
A research letter highlighted recent findings that iREACH educational intervention training may be helpful in preventing peanut allergies.
The latest cardiology case report from Brady Pregerson, MD, features a woman in her 80s presenting with complaints of atrial fibrillation for multiple days. Can you determine the correct diagnosis?
The 2 groups had similar data for any endoscopic recurrence and severe endoscopic recurrence at the first endoscopic evaluation.
New research on Medicare beneficiary data suggests that older adults who face food insecurity concerns may be at greater risk of more rapid declines in cognitive health.
